期刊文献+

102例远处转移鼻咽癌预后因素分析 被引量:3

原文传递
导出
摘要 目的探讨远处转移鼻咽癌预后的影响因素,为临床制定治疗策略及预后的判断提供依据。方法分析2003年1月至2007年12月在四川大学华西医院肿瘤一科就诊的102例远处转移鼻咽癌患者的生存资料,进行生存率计算、单因素及多因素分析。结果远处转移鼻咽癌患者的1、2年生存率分别为54.8%、14.6%,中位生存时间10个月。转移后化疗≥3周期组与化疗<3周期组1、2年生存率对比分别为71.4%vs.40.4%、13.5%vs.13.2%(P=0.080)。单因素分析显示年龄≥60岁、无病生存期(disease-free survival,DFS)<1年、转移后未行化疗、多器官转移、肝转移是远处转移鼻咽癌预后的危险因素。多因素分析显示年龄≥60岁、肝转移、转移后未行化疗、多器官转移是影响远处转移鼻咽癌预后的独立危险因素。结论年龄≥60岁、肝转移、转移后未行化疗、多器官转移是影响远处转移鼻咽癌患者预后的独立危险因素,尽管化疗可以改善远处转移性鼻咽癌患者的预后,但合理的化疗周期数仍需更多研究进一步探寻。
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2011年第4期586-588,共3页 Journal of Sichuan University(Medical Sciences)
  • 相关文献

参考文献18

  • 1Chan AT. Nasopharyngeal carcinoma. Ann Oncol, 2010; 21 (7) :308-312.
  • 2Wolden SL, Chen WC, Pfister DG, et al. Intensity-modulated radiation therapy (IMRT) for nasopharynx cancer: update of the Memorial Sloan-Kettering experience. Int J Radiat Oncol BioI Phys, 2006 ; 64 (1) ; 57-62.
  • 3Lin S, Lu JJ, Han L, et al. Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma: experience of370 consecutive cases. BMCCancer,2010;10:39.
  • 4Lee N, Xia P, Quivey JM, et al. Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma~ an update of the UCSF experience. Int J Radiat Oncol I3iol Phys, 2002;53(1) ;12-22.
  • 5Chiesa F, De Paoli F. Distant metastases from nasopharyngeal cancer. ORI. J Otorhinolaryngol Relat Spec,2001 ;63(4) : 214 216.
  • 6Teo PM, Kwan WH, Lee WY, et al. Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma. Cancer, 1996 ;7(12) :2423-2431.
  • 7Huang CJ, Leung SW, Lian SL, et al. Patterns of distant metastases in nasopharyngeal carcinoma. Kaohsiung J Med Sci, 1996;12(4):229-234.
  • 8谷酰之,殷蔚伯,余子豪等.肿瘤放射治疗学.第4版.北京:中国协和医科大学出版社,2008:443-444.
  • 9Khanfir A, Frikha M, Ghorbel A, et al. Prognostic factors in metastatic nasopharyngeal carcinoma. Cancer Radiothera, 2007~11(8) :461-464.
  • 10周娟,张为民,陈海,谢波,郑积华,徐志勇,林金容.171例转移性鼻咽癌患者的化疗疗效和预后因素分析[J].中华肿瘤杂志,2009,31(11):867-872. 被引量:11

二级参考文献33

  • 1梁翠微,杨兵,李小亮,孙达春.紫杉醇联合顺铂、5-氟尿嘧啶治疗晚期鼻咽癌的临床观察[J].现代肿瘤医学,2006,14(1):14-15. 被引量:6
  • 2唐玲珑,刘立志,马骏,宗井凤,黄莹,林爱华,卢泰祥,崔念基.咽后淋巴结转移在鼻咽癌分期中的意义[J].癌症,2006,25(2):129-135. 被引量:28
  • 3孙燕.内科肿痛学.北京:人民卫生出版社,2001:506-521.
  • 4Lee N,Xia P,Quivey JM,et al.Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma:an update of the UCSF experience.Int J Radiat Oncol Biol Phys,2002,53:12-22.
  • 5Teo PM,Kwan WH,Lee WY,et al.Prognosticators determining survival subsequent to distant metastasis from nasopharyngeal carcinoma.Cancer,1996,77:2423-2431.
  • 6Altun M,Fandi A,Dupos O,et al.Undifferentiated nasopharyngeal cancer (UCNT):current diagnostic and therapeutic aspects.Int J Radiat Oncol Biol Phys,1995,32:859-877.
  • 7Lin JC,Jan JS,Hsu CY.Outpatient weekly chemotherapy in patients with nasopharyngeal carcinoma and distant metastasis.Cancer,1998,83:635-640.
  • 8Schrijvers D,Johnson J,Jiminez U,et al.Phase Ⅲ trial of modulationof cisplatin/fluorouraeil chemotherapy by interferon ulfa-2b in patients with recurrent or metastatic head and neck cancer.Head and Neck Interferon Cooperative Study Group.J Clin Oncol,1998,16:1054-1059.
  • 9Taamma A,Fandi A,Azli N,etal.Phase Ⅱ trial of chermotherspy with 5-fluorouracil,bleomycin,epirubicin,and cisplatin for patients with locally advanced,metastatic,or recurrent undifferentiated carcinoma of the nasopharyngeal type.Cancer,1999,86:1101-1108.
  • 10Hasbini A,Mahjoubi R,Fandi A,et al.Phase Ⅱ trial combining mitomyein with 5-fluorouracil,epirubicin,and eisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.Ann Oncol,1999,10:421-425.

共引文献32

同被引文献27

  • 1吴仕光常见恶性肿瘤综合治疗临床医师导读[M].北京:人民卫生出版社,2007:15.
  • 2Khanfir A, Frikha M, Ghorbel A, et al. Prognostic factors in metastatic nasopharyngeal carcinoma[J]. Cancer Radiother, 2007, 11(8): 461.
  • 3殷蔚伯,余子豪,徐国镇.肿瘤放射治疗学.第四版[M].北京:中国协和医科大学出版社,2008:45.
  • 4Bensouda Y, Kaikani W, Ahbeddou N, et al. Treatment formetastatic nasophaxyrtgeaI carcinoma [J ]. Eur Ann Otorhino- laryngol Head Neck Dis, 2011, 128(2) : 79.
  • 5Bensoucla Y, Kaikani W, Ahbeddou N, et al. Treatment for metastatic nasopharyngeal careinoma[J ]. Eur Ann Otorhino- laryngol Head Neck Dis, 2011, 128(2): 79.
  • 6Desoize B, Madoulet C. Particular aspects of platinum com- pounds used a present in cancer treatment[J]. Crit Rev Oncol Hematol, 2002, 42(3): 317.
  • 7Fuwa N, Kodaira T, Tachibana H, et al. Dose escalation study of nedaplatin with 5 - fluorouraci in combination with alternating radiotherapy in patients with head and neck cancer [J] .Jpn J Clin Oncol, 2007, 37(3) : 161.
  • 8Rojo F, Gracias E, Villena N, et al.Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head andneck: a SEND0 Foundation study[J].Clin Cancer Res, 2010, 16(8): 2474-2482.
  • 9赵充,肖巍魏,韩非,卢丽霞,吴少雄,陈建洲,林承光,黄劭敏,邓小武,卢泰祥,崔念基.419例鼻咽癌患者调强放疗疗效和影响[J].中华放射肿瘤学杂志,2010,19(3):191-196. 被引量:124
  • 10马骏,温浙盛,林鹏,王欣,何洁华.23例鼻咽癌肺转移瘤手术治疗效果的影响因素分析[J].中国肿瘤临床,2010,37(14):804-807. 被引量:2

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部